saijujacob

Prof Saiju Jacob

MBBS, MD, DPhil, FRCP, FAAN

Consultant Neurologist

About us

Base NHS Hospital

University Hospitals Birmingham NHS Foundation Trust

Edgbaston, Birmingham. B15 2TH

Private Practices

The Harborne Hospital

Mindelsohn Way

Birmingham

B15 2FQ

Private Practices

The Priory Hospital

Priory Road

Birmingham

B5 7UG

Private Practices

Spire Parkway Hospital

1 Damson Parkway

Solihull

B91 2PP

About

Saiju Jacob is a Consultant Neurologist at the University Hospitals of Birmingham NHS Foundation Trust. He holds an Honorary Professorship at the Institute of Immunology and Immunotherapy, University of Birmingham. 

Saiju did his early Neurology training at the Atkinson Morley’s (St George’s) Hospital in London and later joined the West Midlands Deanery training rotation (Leicester, Coventry and Birmingham). He has undertaken original doctoral research under the guidance of Prof Angela Vincent at the Weatherall Institute of Molecular Medicine and the John Radcliffe Hospital in Oxford. His clinical and research interests include neuroimmunological aspects of peripheral and central nervous system disorders.

At the Queen Elizabeth Neuroscience Centre (University Hospitals of Birmingham) he has a weekly clinic for General Neurology, Neuromuscular diseases and Neuroimmunology. Patients can be referred to this NHS clinic by the GP or other NHS consultants.

In addition to his clinical work, Saiju Jacob is in the National Council and Research Committee of the Association of British Neurologists, and is a member of the ABN Specialist Advisory Group on MS/Neuroinflammation and Neuromuscular Diseases. He is also a Board member of the Myasthenia Gravis charity, Myaware. Saiju is the Neurology Clinical Specialty Lead for NIHR Research Delivery Network (West Midlands) – Neurological Disorders and Co-lead for Dendron (Dementia and Neurodegeneration). 

Saiju has active undergraduate and postgraduate teaching commitments and is the rotations Training Programme Director for Neurology at the Health Education England – West Midlands. He regularly has international and doctoral research fellows under his supervision. 

Saiju Jacob currently has private practising privileges at the HCA Harborne Hospital, Circle Priory Hospitals, Birmingham and the Spire Parkway Hospitals, Solihull UK.

​For appointments please contact – secretary (07907 693108) or the hospitals directly (BMI, 0121 4461638 or .Spire, 0121 7045530). 

Neuroimmunology laboratory services are undertaken at the University of Birmingham. Details of the tests performed can be accessed through http://www.birmingham.ac.uk/facilities/clinical-immunology-services/neuroimmunology/index.aspx

Memberships

Royal College of Physicians (UK)
Association of British Neurologists
American Academy of Neurology
Eurpean Academy of Neurology
International Society of Neuroimmunology
International League Against Epilepsy
British Peripheral Nerve Society
Medical Defence Union

Selected Publications

  1. Bonar K, Boudiaf N, Zaremba P, Tarancón T, Zhou J, Jacob S. Disease burden, healthcare resource utilisation, and treatment patterns in patients with newly diagnosed myasthenia gravis in England: A retrospective cohort study. J Neuromuscul Dis. 2025 Jan-Feb;12(1):22143602241308194.
  2. Nazeer KK, Alatrash S, Elsheikh S, Jacob S. Xanthomatous hypophysitis relapsing and remitting over two decades. Pract Neurol. 2025 Jan 30:pn-2024-004430. 
  3. Moniz Dionísio J, Ambrose P, Burke G, Farrugia ME, Garcia-Reitboeck P, Hewamadduma C, Hill M, Howard RS, Jacob S, Kullmann D, Leite MI, Miller J, Pinto A, Pritchard J, Riswick T, Sathasivam S, Thambirajah N, Viegas S, Norwood F, Spillane J. Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience. J Neurol Neurosurg Psychiatry. 2025 Jan 11:jnnp-2024-334086.
  4. Rashid W, Ciccarelli O, Leary SM, Arun T, Doshi A, Evangelou N, Ford HL, Hobart J, Jacob S, Muraro PA, Murray K, Palace J, Dobson R; Association Of British Neurologists Multiple Sclerosis and Neuroinflammation Advisory Group. Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. Pract Neurol. 2025 Jan 16;25(1):18-24. 
  5. Nagy S, Pagnamenta AT, Cali E, Braakman HMH, Wijntjes J, Kusters B, Gotkine M, Elpeleg O, Meiner V, Lenberg J, Wigby K, Friedman J, Perry LD, Rossor AM, Uhrova Meszarosova A, Thomasova D, Jacob S, O’Driscoll M, De Simone L, Grange DK, Sommerville R, Firoozfar Z, Alavi S, Mazaheri M, Parmar JM, Lamont PJ, Pini V, Sarkozy A, Muntoni F, Ravenscroft G, Jones E, O’Rourke D, Nel M, Heckmann JM, Kvalsund M, Kapapa MM, Wa Somwe S, Bearden DR, Çakar A, Childs AM, Horvath R, Reilly MM, Houlden H, Maroofian R. Autosomal recessive VWA1-related disorder: comprehensive analysis of phenotypic variability and genetic mutations. Brain Commun. 2024 Oct 28;6(6):fcae377.
  6. Bose S, Jacob S. Stiff-person syndrome. Pract Neurol. 2025 Jan 16;25(1):6-17.
  7. Jacob S. Treating myasthenia gravis beyond the eye clinic. Eye (Lond). 2024 Aug;38(12):2422-2436.
  8. van Enkhuizen J, Binns J, Betts A, Hosnijeh FS, Alexander M, McCormack M, Jacob S. A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England. Ther Adv Neurol Disord. 2024 Apr 16;17:17562864241237495. 
  9. Dodd KC, Ahmed R, Ambrose P, Holt JK, Jacob S, Leite MI, Miller JA, San PP, Spillane J, Viegas S, Sussman J. Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis. Neuromuscul Disord. 2024 May;38:51-57. 
  10. Binks SNM, Veldsman M, Handel AE, Jacob S, Maddison P, Coebergh J, Michael S, Ramanathan S, Easton A, Nissen MS, Leite MI, Okai D, Blaabjerg M, Husain M, Irani SR. Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis. Ann Clin Transl Neurol. 2024 Apr;11(4):1053-1058.
  11. Saccà F, Salort-Campana E, Jacob S, Cortés-Vicente E, Schneider-Gold C. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol. 2024 Jun;31(6):e16180.
  12. San PP, Jacob S. Role of complement in myasthenia gravis. Front Neurol. 2023 Oct 5;14:1277596. 
  13. Rogers JP, Chou MKL, Pollak TA, Eyre M, Krutikov M, Church A, Hart MS, Karim A, Michael S, Vincent A, David AS, Lewis G, Jacob S, Zandi MS. Seasonal variation and temporal relationship to the COVID-19 pandemic of NMDA receptor antibody results. J Neurol. 2023 Nov;270(11):5182-5187. 
  14. Bose S, Papathanasiou A, Karkhanis S, Appleton JP, King D, Batra R, Mollan SP, Jacob S. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). J Neurol. 2023 Dec;270(12):6193-6206. 
  15. Nair SS, Jacob S. Novel Immunotherapies for Myasthenia Gravis. Immunotargets Ther. 2023 Apr 4;12:25-45. 
  16. Gövert F, Abrante L, Becktepe J, Balint B, Ganos C, Hofstadt-van Oy U, Krogias C, Varley J, Irani SR, Paneva S, Titulaer MJ, de Vries JM, Boon AJW, Schreurs MWJ, Joubert B, Honnorat J, Vogrig A, Ariño H, Sabater L, Dalmau J, Scotton S, Jacob S, Melzer N, Bien CG, Geis C, Lewerenz J, Prüss H, Wandinger KP, Deuschl G, Leypoldt F. Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis. Brain. 2023 Feb 13;146(2):657-667. 
  17. Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S. A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurol. 2022 May 9;22(1):172.
  18. Papathanasiou A, Tanasescu R, Tench CR, Rocha MF, Bose S, Constantinescu CS, Jacob S. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. J Neurol Sci. 2021 Dec 15;431:120039.
  19. Jacob S, Mazibrada G, Irani SR, Jacob A, Yudina A. The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review. J Neuroimmune Pharmacol. 2021 Dec;16(4):806-817
  20. Siddiqi ZA, Nowak RJ, Mozaffar T, O’Brien F, Yountz M, Patti F; REGAIN Study Group. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve. 2021 Dec;64(6):662-669.
  21. Bose, S., Thompson, J.T., Sadalage, G., Karim, A., Jacob, S. (2021), Quantitative assessment of resonse to long term treatment with IVIG in patients with Stiff Person Syndrome. Mov Disord Clin Pract, https://doi.org/20/1002/mdc3.13261.
  22. Sangeeta Scotton, Mei See, Varduhi Cahill, Piers Newman, Girija Sadalage, KP Divya, Ajith Cherian, Saiju Jacob. Caspr2 antibody associated movement disorders – a case series. J Neurol (2021 Jan 5)
  23. Muppidi S, Guptill JT, Jacob S, et al for the CARE-MG study group. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol 2020 Dec; 19(12):970-971. 
  24. Sawlani, V., Patel, M. D., Davies, N., Flintham, R., Wesolowski, R., Ughratdar, I., Pohl, U., Nagaraju, S., Petrik, V., Kay, A., Jacob, S., Sanghera, P., Wykes, V., Watts, C., & Poptani, H. (2020). Multiparametric MRI: practical approach and pictorial review of a useful tool in the evaluation of brain tumours and tumour-like lesions. Insights into imaging, 2020; 11(1), 84.
  25. Vijay Sawlani, Sangeeta Scotton, Kurdow Nader, Jian Ping Jen, Markand Patel, Karishma Gokani, Peter Denno, Mark Thaller, Christina Englezou, Umair Janjua, Michael Bowen, Chandrashekar Hoskote, Tonny Veenith, Ghaniah Hassan-Smith, Saiju Jacob. COVID-19 related intracranial imaging findings: a large single-centre experience. Clin Radiol 2020 Oct. 
  26. Mantegazza R, O’Brien FL, Yountz M, Howard JF Jr; REGAIN study group. Consistent improvement with Eculizumab across muscle groups in Myasthenia Gravis. Ann Clin Transl Neurol. 2020 Jul 22. doi: 10.1002/acn3.51121.
  27. Saiju Jacob, Hiroyuku Murai, Kimiaki Utsugisawa, Richard Nowak, Heinz Wiendl, Kenju Fujita, Fanny O’Brien, James Howard and the REGAIN study group. Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Ther Adv Neurol Disord 2020 May 6;13:1756286420911784 (Clinical Trial).
  28. Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ. Guidance for the management of Myasthenia Gravis (MG) and Lambert Eaton Myasthenic Syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020 May 15;412:116803.
  29. Vissing J, Jacob S, Fujita KP, O’Brien F, Howard JF; REGAIN study group. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody- positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020 Jul;267(7):1991-2001. 
  30. Miller TD, Chong TT, Aimola Davies AM, Johnson MR, Irani SR, Husain M, Ng TW, Jacob S, Maddison P, Kennard C, Gowland PA, Rosenthal CR. Human hippocampal CA3 damage disrupts both recent and remote episodic memories. Elife. 2020 Jan 24;9:e41836.
  31. Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O’Brien F, Wang JJ, Fujita KP, Utsugisawa K; REGAIN Study Group. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. J Neurol Sci. 2019 Dec 15;407:116419 (Clinical Trial).
  32. Saiju Jacob, Angela Vincent Autoimmune Encephalitis, Emergencies in Neurology 2020 Vol II. ISBN 978-981-13-7379-4. (Textbook chapter).
  33. Saiju Jacob. Guillain Barré syndrome. BMJ Best Practice 2019 Nov (Review article).
  34. Thompson DC, Bailey MS RAMC, Bowley D, Jacob S. Encephalitis on deployment in Kenya: think beyond the infections. J R Army Med Corps. 2019 Oct;165(5):374-376 (Case Report).
  35. White D, Mollan SP, Ramalingam S, Nagaraju S, Hayton T, Jacob S. Enlarged and Enhancing Optic Nerves in Advanced Glial Fibrillary Acidic Protein Meningoencephalomyelitis. J Neuroophthalmol. 2019 Sep;39(3):411-415 (Case Report).
  36. Jacob S. Primary angiitis of the central nervous system (PACNS) – a rare and serious, but treatable entity (Editorial). Neurol India. 2019 May-Jun;67(3):942-944 (Editorial).  
  37. Bose S, Jacob S. Restless leg syndrome in patients with liver cirrhosis: Waiting for the shoe to drop. Neurol India. 2019 May-Jun;67(3):657-659 (Editorial). 
  38. Andersen H, Mantegazza R, Wang JJ, O’Brien F, Patra K, Howard JF Jr; REGAIN Study Group. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019 Aug;28(8):2255 (Clinical Trial). 
  39. Maddison P, Sadalage G, Ambrose PA, Jacob S, Vincent A. False-positive acetylcholine receptor antibody results in patients without myasthenia gravis. J Neuroimmunol. 2019 Apr 3;332:69-72 (Original Research).  
  40. Nahari Y, Abbas A, Curtis E, Jacob S. Slowly progressive distal muscle weakness: neuropathy or myopathy? BMJ Case Rep.2019 Apr 3;12(4) (Case Report). 
  41. Andersen H, Mantegazza R, Wang JJ, O’Brien F, Patra K, Howard JF Jr; REGAIN Study Group. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019 Mar 23 (Clinical Trial). 
  42. Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S. Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England. J Med Econ. 2019 Mar 7:1 (Original research).
  43. Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, et al for the REGAIN Study Group. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019 Feb 14 (Clinical Trial). 
  44. Scotton WJ, Karim A, Jacob S. Glutamate Receptor Antibodies in Autoimmune Central Nervous System Disease: Basic Mechanisms, Clinical Features, and Antibody Detection. Methods Mol Biol. 2019;1941:225-255 (Textbook Chapter).
  45. Saiju Jacob. Myasthenia Gravis – A review of current therapeutic options. Eur Neurol Review 2018;13 (2):86-92 (Review).
  46. Saiju Jacob Refractory Myasthenia Gravis – Patient Burden and the need for new therapeutic targets. Eur Neurol Review2018;13 (1): 18-20 (Review). 
  47. Binks S, Varley J, Lee W, Makuch M, Elliott K, Gelfand JM, Jacob S, Leite MI, Maddison P, Chen M, Geschwind MD, Grant E, Sen A, Waters P, McCormack M, Cavalleri GL, Barnardo M, Knight JC, Irani SR. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain. 2018 May 18 (Original Research).  
  48. Wilson R, Menassa DA, Davies AJ, Michael S, Hester J, Kuker W, Collins GP, Cossins J, Beeson D, Steven N, Maddison P, Rinaldi S, Jacob S, Irani SR. Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol. 2018 Mar 25;5(5):640-645 (Original Research). 
  49. Vincent A, Huda S, Cao M, Cetin H, Koneczny I, Rodriguez-Cruz P, Jacobson L, Viegas S, Jacob S, Woodhall M, Nagaishi A, Maniaol A, Damato V, Leite MI, Cossins J, Webster R, Palace J, Beeson D. Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci. 2018 Feb;1413(1):143-153 (Review). 
  50. Saiju Jacob. Refractory Myasthenia Gravis: patient burden and the need for new therapeutic targets. European Neurological Review 2018; 13 (1): 18-20 (Review). 
  51. Karim A, Jacob S. Annals Express: Experience with newer central nervous system autoantibodies. Ann Clin Biochem. 2018 Jan 55 (1): 7-17. (Review). 
  52. Howard JF, Utsugisawa K, Benater M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O’Brien F, Wang JJ, Mantegazza R. REGAIN: A randomised, double-blind, placebo-controlled, multi-centre study to evaluate the safety and efficacy of eculizumab in patients with anti-acetylcholine receptor-positive refractory generalised myasthenia gravis. Lancet  Neurol 2017; 16(12): 976-986 (Clinical Trial). 
  53. Samra K, Boon IS, Packer G, Jacob S. Lethal high: acute disseminated encephalomyelitis (ADEM) triggered by toxic effect of synthetic cannabinoid black mamba. BMJ Case Rep. 2017 Apr 22;2017. (Case Report). 
  54. Meininger V, Jacob S. et al and the NOG112264 Study Group. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar;16(3):208-216. (Clinical Trial). 
  55. Karim A, Patel D, Jacob S. Guidelines on optimal laboratory testing of paraneoplastic antibodies. UKNEQAS Neuroimmunology Cellular & Molecular Biology – 2017 April (Review). 
  56. Miller TD, Chong TT, Aimola Davies AM, Ng TW, Johnson MR, Irani SR, Vincent A, Husain M, Jacob S, et al. Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain. 2017; 140 (5): 1212-1219. (Original research). 
  57. Brady S, Healy EG, Gang Q, Parton M, Quinlivan R, Jacob S, et al. Tubular Aggregates and Cylindrical Spirals Have Distinct Immunohistochemical Signatures. J Neuropathol Exp Neurol. 2016 Dec;75(12):1171-1178. (Experimental research).  
  58. Ahmed Abbas, Ashish Garg, Rajdeep Jain, Gordon Mazibrada, Saiju Jacob. Extreme delta brush and BIRDS in NMDAR encephalitis. Pract Neurol, 2016, 16(4): 326-7. (Case report).
  59. Karim A, Egner W,  Patel D, Richter A, Jacob S. International consensus – paraneoplastic neurological antibodies – are we there yet? J Clin Exp Neuroimmunol 2016;1:1 (Review).
  60. Saiju Jacob. Autoimmune encephalitis – an evolving spectrum Neurology India, 2015 Sep-Oct (Editorial). 
  61. Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, Brown R, Moss K, McNeillis B, Goh YY, Leite MI, Robertson N, Palace J, Jacob A. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum  disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014 Mar 19. (Observational study).
  62. Rickards H, Jacob S, Lennox B, Nicholson T. Autoimmune encephalitis and mental disorders. Advances in Psychiatric Treatment (2014) (Review article).
  63. Boukouvala S, Jacob S, Lane M, Denniston AK, Burdon MA. Detection of branch retinal artery occlusions in Susac’s syndrome. BMC Res Notes. 2014 Jan 21;7(1):56. (Case Report).
  64. Jacob S, Rajabally YA. Immunomodulation in Inflammatory Neuropathies: Rationale and Safety. Curr Drug Saf. 2013 Sep;8(4):225-35. (Review).
  65. Jacob S, Vincent A. Autoimmune Myasthenias, Muscle Disease: Pathology and Genetics, Eds. Goebel HH, Sewry CA, Weller RO. (2013) (Textbook chapter).
  66. Jacob S, Viegas S, Hilton-Jones D. Myasthenia gravis, Oxford Text book of Clinical Neurology (Neuromuscular disorders) Eds. Hilton-Jones D, Turner, M. (2013) (Textbook chapter).
  67. Jacob S, Viegas S, Leite MI et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia. Arch Neurol 2012;69:994-1001. (Experimental research).
  68. Viegas S, Jacobson L, Waters P, Cossins J, Jacob S, Leite MI, Webster R, Vincent A. Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Exp Neurol. 2012;234:506-12. (Original article).
  69. Karim A and Jacob S. Immunological markers in neurological disorders. Ann Clin Biochem 2012;49:29-43 (Review). Revised 2015.
  70. Saiju Jacob, John Winer. Guillain Barré syndrome. BMJ Best Practice (2011) (Review article).
  71. Saiju Jacob. Myasthenic syndromes. In Woodward S (Eds), Text book of Neuroscience Nursing. Blackwell publishing, Oxford (2011) (Textbook chapter).
  72. An aid to MRCP PACES, Ryder J (eds). Text book chapter 2011 (multiple chapters).
  73. Karim A, Jacob S. Neuroimmunology. In Hall A, Yates S (Eds) Immunology, Fundamentals of Biomedical Science (2010) (Textbook chapter).
  74. Jacob S, Rajabally Y. Current proposed mechanism of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 2009; 7: 337-42. (Review).
  75. Saiju Jacob, Stuart Viegas, Daniel Lashley, David Hilton-Jones. Myasthenia gravis and other neuromuscular junction disorders. Pract Neurol 2009; 9: 364-371. (Review).
  76. Schoser B, Jacob S, Hilton-Jones D, et al. Immune mediated rippling muscle disease with myasthenia gravis: a report of seven patients with long-term follow-up in two. Neuromusc Dis 2009; 19: 223-8. (Original article).
  77. Farrugia ME, Jacob S, Sarrigiannis PG, Kennet R. Correlating the extent of neuromuscular instability with acetylcholine receptor antibodies. Muscle Nerve 2009; 39:489-93. (Original article).
  78. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, et al.  Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008;65:913-9. (Original research).
  79. Vincent A, Leite MI, Farrugia ME, Jacob S, et al.  Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci. 2008;1132:84-92. (Review article).
  80. Leite MI, Jacob S, Viegas S, et al.  IgG1 antibodies to acetylcholine receptors in “seronegative” MG. Brain 2008;131:1940-52 (Original article).
  81. Jacob S, Irani S, et al. Hypothermia in VGKC antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry 2008;79(2):202-4. (Case report).
  82. Rajabally YA, Jacob S. Chronic inflammatory demyelinating polyneuropathy-like disorder associated with amyotrophic lateral sclerosis. Muscle Nerve. 2008;38:855-60. (Original article).
  83. Jacob S, Saha AR, Rajabally Y. Post-traumatic short-lasting unilateral headache with cranial autonomic symptoms (SUNA). Cephalalgia 2008;28(9):991-3. (Case report).
  84. Jacob S, Leite MI, et al. IgG subclasses of disease-specific autoantibodies and complement activation in-vitro in myasthenia gravis and neuromyelitis optica. Mol Immunol 2007;44:3938. (Experimental research).
  85. Jacob S, Viegas S, Hilton-Jones D, Willcox N. The perioperative management of thymectomy in myasthenia gravis: an overview. Br J Neurosc Nurs 2007;3:261-4 (Review article).
  86. Saiju Jacob, Stuart Viegas, David Hilton-Jones. Assessment and management of myasthenic crisis: an evidence based approach. Br J Neurosc Nurs 2007;3:198-204 (Review article).
  87. Viegas S, Jacob S, Hilton-Jones D. The pathogenesis of myasthenic syndromes: a practical guide to diagnosis and management. Br J Neurosc Nurs 2007;3:152-7 (Review article).
  88. Saiju Jacob, Yusuf Rajabally, Maxwell Damian. Charcot Marie Tooth disease Type 1A associated with acute porphyric neuropathy Eur J Neurol 2007:14:e10-11 (Letter).
  89. S. Jacob, Y. Rajabally. Short-lasting unilateral neuralgiform headache with autonomic symptoms (SUNA) secondary to vertebral artery dissection. Cephalalgia 2007;27:283-5 (Case report).
  90. Rajabally YA, Jacob S. Proximal nerve conduction studies in chronic inflammatory demyelinating neuropathy Clin Neurophys2006;117:2079-84 (Original article).
  91. Yusuf A. Rajabally, Saiju Jacob, Richard J. Abbott. Clinical heterogeneity in mild Chronic Inflammatory Demyelinating Polyneuropathy. Eur Neurol 2006:13:958-62 (Original article). 
  92. Jacob S, Pye E, Hbahbih M, Messios N, Rajabally Y. Rapidly progressive bilateral ophthalmoplegia and enlarging mass caused by amelanotic melanoma. J Neuro-ophthal 2006;26(1):49-50.
  93. Jacob S, Martin D, Rajabally Y. Juvenile myoclonic epilepsy in an elderly patient. Age Ageing 2006;35(2):194-6.
  94. Yusuf A Rajabally, Saiju Jacob, Majed Hbahbih. Optimising the use of electrophysiology in the diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy – A Study of 20 cases (Research Report). J Periph Nerv System 2005;10:282-292. (Original article).
  95. Saiju Jacob, Mojtaba Zarei, Anthony Kenton, Holger Allroggen. Gluten sensitivity and Neuromyelitis optica – Two case reports.  J Neurol Neurosurg Psychiatry 2005;76:1028-1030.
  96. Saiju Jacob, Yusuf A Rajabally. Hashimoto’s encephalopathy – steroid resistance and response to immunoglobulins. J Neurol Neurosurg Psychiatry 2005;76:455-456.
  97. Rajabally YA, Jacob S. Hemicrania continua responsive to Verapamil. Headache 2005;45(8):1082-3. (Case report).
  98. S Jacob, Y A Rajabally Intracranial hypertension induced by  Rofecoxib. Headache 2005;45:75-6.
  99. Rajabally YA, Jacob S. Neuropathy associated with lansoprazole treatment. Muscle Nerve 2005;31:124-125.

Specialising in general neurology and neuroimmunology

Registered with most insurance providers

Appointments

Contact:

Private secretary – Lisa – 07907 693108 (Email – lisaalsop@protonmail.com)

HCA Harborne Hospital – 0121 8123051
Circle Group Priory Hospital, Edgbaston – 0121 4461638
Spire Parkway Hospital, Solihull – 0121 7045530